Banner placeholder

Welcome to EUSA Pharma

EUSA Pharma is a newly formed specialty pharmaceutical company headquartered in the UK which supplies medicines and medical devices across Europe through its own operations, and worldwide through a network of partners in over 40 countries.

Please contact:
EUSA Pharma Corporate Headquarters for more information on EUSA Pharma.
EUSA Pharma Customer Services for information on how to order all EUSA Pharma products.
EUSA Pharma Medical Information Department for all medical information enquiries.
EUSA Pharma Product Safety to report any safety concerns with any EUSA Pharma product.


EUSA Pharma Acquires Global Rights to neuroblastoma treatment Isqette® (dinutuximab beta) from Apeiron Biologics

HEMEL HEMPSTEAD, England and VIENNA, Austria – 4 October 2016

EUSA Pharma (EUSA), a specialty pharmaceutical company with a focus on oncology and oncology supportive care, today announced the acquisition of exclusive global commercialization rights to the oncology product Isqette (dinutuximab beta) from Apeiron Biologics. The immunotherapy has orphan drug designation in the US and EU and is currently under review for marketing authorization by the EMA.
Click here to download the press release (PDF)


EUSA Pharma launches a US Caphosol Reimbursement Program

HAMILTON, NJ USA – 30 September 2016

US Caphosol Reimbursement Program (Only for US Residents)

If you wish to know more / are eligible / apply, please click here

CAPP Application Form (Only for US Residents)

Please click here to download

All News ►